TD Cowen Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1030
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Tyler Van Buren maintains a Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and raises the price target from $1020 to $1030.

April 24, 2024 | 5:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TD Cowen reaffirms a Buy rating on Regeneron Pharmaceuticals and increases the price target to $1030.
The upgrade in the price target by TD Cowen reflects a positive outlook on Regeneron Pharmaceuticals, likely due to strong performance or positive future expectations. This endorsement from a reputable analyst could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100